showed that a DR5-targeting antibody-drug conjugate combined with a CDK inhibitor synergistically suppressed tumor growth in advanced CRC models, including chemotherapy-resistant settings
[1] [2] As with other agents in this class, gallbladder-related events (such as gallstones) are a potential concern and warrant monitoring, consistent with class precedents
Oral tirzepatide Oral formulations of tirzepatide are in development, and some compounding pharmacies already offer tirzepatide drops and orally disintegrating tablets
Ramos, and K
Singhania, N., Devi, K.B., Kaur, J., Bhansali, A., Gorsi, U., Sachdeva, N., Arora, S., Rai, A
On the other hand, integrase inhibitorsa newer class of HIV medicationsdont appear to interfere with hormonal birth control, making them a safer pairing in most cases